EyePoint Pharmaceuticals (EYPT) Reports Q1 Loss, Tops Revenue Estimates

Group 1 - EyePoint Pharmaceuticals reported a quarterly loss of $0.65 per share, which aligns with the Zacks Consensus Estimate, compared to a loss of$0.55 per share a year ago [1] - The company posted revenues of $24.45 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 345.17$11.68 million year-over-year [2] - The stock has underperformed, losing about 16.1% since the beginning of the year, while the S&P 500 declined by 4.7% [3] Group 2 - The earnings outlook for EyePoint Pharmaceuticals is mixed, with the current consensus EPS estimate for the coming quarter at -$0.67 on revenues of$5.49 million, and -$2.84 on revenues of$13.96 million for the current fiscal year [7] - The Medical - Biomedical and Genetics industry, to which EyePoint Pharmaceuticals belongs, is currently in the top 35% of Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - The estimate revisions trend for EyePoint Pharmaceuticals is currently reflected in a Zacks Rank 3 (Hold), suggesting the stock is expected to perform in line with the market in the near future [6]